BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 87 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,996 | -86.5% | 14,978 | +39.5% | 0.00% | – |
| Q2 2023 | $22,122 | -38.6% | 10,739 | -1.8% | 0.00% | – |
| Q1 2023 | $36,008 | +125.0% | 10,939 | -0.9% | 0.00% | – |
| Q4 2022 | $16,000 | -66.7% | 11,039 | +1.8% | 0.00% | – |
| Q3 2022 | $48,000 | +54.8% | 10,839 | 0.0% | 0.00% | – |
| Q2 2022 | $31,000 | -97.7% | 10,839 | 0.0% | 0.00% | -100.0% |
| Q1 2022 | $1,329,000 | +3222.5% | 10,839 | +7.1% | 0.00% | – |
| Q4 2021 | $40,000 | +8.1% | 10,120 | -7.3% | 0.00% | – |
| Q3 2021 | $37,000 | -11.9% | 10,920 | 0.0% | 0.00% | – |
| Q2 2021 | $42,000 | -54.3% | 10,920 | -54.5% | 0.00% | – |
| Q1 2021 | $92,000 | -7.1% | 23,981 | +10.2% | 0.00% | – |
| Q4 2020 | $99,000 | -89.6% | 21,761 | -61.2% | 0.00% | -100.0% |
| Q3 2020 | $948,000 | +989.7% | 56,104 | +619.3% | 0.00% | – |
| Q2 2020 | $87,000 | +117.5% | 7,800 | -8.2% | 0.00% | – |
| Q1 2020 | $40,000 | – | 8,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 241,500 | $1,093,000 | 0.17% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 90,584 | $410,000 | 0.13% |
| EPIQ PARTNERS, LLC | 10,550 | $48,000 | 0.03% |
| Phoenix Holdings Ltd. | 173,683 | $799,000 | 0.02% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 5,500 | $25,000 | 0.02% |
| CFO4Life Group, LLC | 12,003 | $54,000 | 0.02% |
| HighPoint Advisor Group LLC | 15,733 | $115,000 | 0.01% |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 357,761 | $1,619,000 | 0.01% |
| Virtu Financial LLC | 24,484 | $111,000 | 0.01% |
| ETF MANAGERS GROUP, LLC | 93,902 | $435,000 | 0.01% |